适应症-话题@MedSci

#适应症#

219篇内容 | 3028人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336822, encodeId=1f9c1336822ab, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=紫苑生物与捷思英达达成许可协议，引进AT-0287非肿瘤适应症全球开发权益, objectType=article, longId=202876, objectId=75e92028e64c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e92028e64c, replyNumber=0, likeNumber=52, createdTime=2020-11-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e92028e64c, moduleTitle=紫苑生物与捷思英达达成许可协议，引进AT-0287非肿瘤适应症全球开发权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e92028e64c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336821, encodeId=9f141336821bb, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, objectType=article, longId=201089, objectId=b23f201089dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b23f201089dc, replyNumber=0, likeNumber=81, createdTime=2020-09-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b23f201089dc, moduleTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b23f201089dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336820, encodeId=f4711336820c4, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=77, createdTime=2020-09-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336819, encodeId=8be4133681931, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, objectType=article, longId=200589, objectId=14462005895e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14462005895e, replyNumber=0, likeNumber=55, createdTime=2020-09-13, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14462005895e, moduleTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14462005895e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336818, encodeId=8d2013368187d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Gastric Cancer：符合扩大适应症标准的早期胃癌内镜黏膜下剥离技术难度的相关因素, objectType=article, longId=196961, objectId=187f196961f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187f196961f7, replyNumber=0, likeNumber=64, createdTime=2020-07-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187f196961f7, moduleTitle=Gastric Cancer：符合扩大适应症标准的早期胃癌内镜黏膜下剥离技术难度的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187f196961f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336817, encodeId=de9d133681e19, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症, objectType=article, longId=196062, objectId=59a819606271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59a819606271, replyNumber=0, likeNumber=67, createdTime=2020-06-19, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a819606271, moduleTitle=FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a819606271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336816, encodeId=b6561336816f9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗, objectType=article, longId=194917, objectId=cfd319491ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd319491ed0, replyNumber=0, likeNumber=60, createdTime=2020-05-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd319491ed0, moduleTitle=又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd319491ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336815, encodeId=437c1336815d7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=75, createdTime=2020-05-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336814, encodeId=f97f133681459, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=中国上市的适应症！罗氏VENTANA PD-L1（SP263）检测作为治疗尿路上皮癌的伴随诊断获批上市, objectType=article, longId=194187, objectId=a31b19418e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a31b19418e54, replyNumber=0, likeNumber=57, createdTime=2020-05-17, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a31b19418e54, moduleTitle=中国上市的适应症！罗氏VENTANA PD-L1（SP263）检测作为治疗尿路上皮癌的伴随诊断获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a31b19418e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336813, encodeId=aec41336813f2, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理, objectType=article, longId=193780, objectId=7cfe193e80fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfe193e80fe, replyNumber=0, likeNumber=51, createdTime=2020-05-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfe193e80fe, moduleTitle=君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfe193e80fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336812, encodeId=c30a133681234, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, objectType=article, longId=193374, objectId=b40b1933e4d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b1933e4d3, replyNumber=0, likeNumber=63, createdTime=2020-05-03, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b1933e4d3, moduleTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40b1933e4d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336811, encodeId=c3331336811ac, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=可善挺（司库奇尤单抗）强直性脊柱炎适应症获批, objectType=article, longId=193217, objectId=d1c619321e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1c619321e2d, replyNumber=0, likeNumber=73, createdTime=2020-05-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1c619321e2d, moduleTitle=可善挺（司库奇尤单抗）强直性脊柱炎适应症获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1c619321e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336810, encodeId=f2f51336810e4, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, objectType=article, longId=192965, objectId=ea1f19296574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1f19296574, replyNumber=0, likeNumber=64, createdTime=2020-04-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1f19296574, moduleTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1f19296574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336809, encodeId=0c001336809e7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者, objectType=article, longId=192258, objectId=2e6b19225867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6b19225867, replyNumber=0, likeNumber=68, createdTime=2020-04-16, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6b19225867, moduleTitle=连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6b19225867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336808, encodeId=192713368082e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩大EUCRISA（Crisaborole）软膏适应症：至3个月大的轻中度特应性皮炎患儿, objectType=article, longId=190849, objectId=47a6190849f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47a6190849f1, replyNumber=0, likeNumber=96, createdTime=2020-03-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47a6190849f1, moduleTitle=FDA扩大EUCRISA（Crisaborole）软膏适应症：至3个月大的轻中度特应性皮炎患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47a6190849f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336807, encodeId=dcd2133680ef7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=U.S. FOOD & DRUG: FDA授予瑞德西韦“孤儿药”资格，适应症为COVID-19, objectType=article, longId=190840, objectId=34ef190840fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ef190840fc, replyNumber=0, likeNumber=63, createdTime=2020-03-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ef190840fc, moduleTitle=U.S. FOOD & DRUG: FDA授予瑞德西韦“孤儿药”资格，适应症为COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34ef190840fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336806, encodeId=f1141336806f9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=纳武利尤单抗在中国获批胃癌三线治疗适应症, objectType=article, longId=190253, objectId=8e7b19025337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7b19025337, replyNumber=0, likeNumber=154, createdTime=2020-03-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7b19025337, moduleTitle=纳武利尤单抗在中国获批胃癌三线治疗适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7b19025337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336805, encodeId=0b90133680523, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, objectType=article, longId=189668, objectId=1f7f18966870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7f18966870, replyNumber=0, likeNumber=63, createdTime=2020-03-12, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7f18966870, moduleTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f7f18966870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336804, encodeId=927113368042a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=专家：上海收治第一个患者起，就开始老药新用扩大适应症研究, objectType=article, longId=189480, objectId=8edf1894806d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8edf1894806d, replyNumber=0, likeNumber=62, createdTime=2020-03-07, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8edf1894806d, moduleTitle=专家：上海收治第一个患者起，就开始老药新用扩大适应症研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8edf1894806d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336803, encodeId=f0a013368036e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验, objectType=article, longId=187867, objectId=62a518e86745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62a518e86745, replyNumber=0, likeNumber=48, createdTime=2020-02-13, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62a518e86745, moduleTitle=海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62a518e86745)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

紫苑生物与捷思英达达成许可协议，引进AT-0287非肿瘤适应症全球开发权益

2020-11-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗

2020-09-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2020-09-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性

2020-09-13

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Gastric Cancer：符合扩大适应症标准的早期胃癌内镜黏膜下剥离技术难度的相关因素

2020-07-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症

2020-06-19

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗

2020-05-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!

2020-05-20

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

中国上市的适应症！罗氏VENTANA PD-L1（SP263）检测作为治疗尿路上皮癌的伴随诊断获批上市

2020-05-17

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理

2020-05-10

仁心济世 (审核中...)

前往app查看评论内容

#适应症#

FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗

2020-05-03

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

可善挺（司库奇尤单抗）强直性脊柱炎适应症获批

2020-05-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症

2020-04-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者

2020-04-16

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA扩大EUCRISA（Crisaborole）软膏适应症：至3个月大的轻中度特应性皮炎患儿

2020-03-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

U.S. FOOD & DRUG: FDA授予瑞德西韦“孤儿药”资格，适应症为COVID-19

2020-03-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

纳武利尤单抗在中国获批胃癌三线治疗适应症

2020-03-20

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病

2020-03-12

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

专家：上海收治第一个患者起，就开始老药新用扩大适应症研究

2020-03-07

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验

2020-02-13

科室
- - 订阅+
  - 更多科室
工具
服务